Darbepoetin tracked more hemangiomas; adjustment weakened the signal
In one 390-infant retrospective cohort, hemangioma was documented before discharge in 17/92 darbepoetin-exposed infants versus 18/262 unexposed. The crude OR of 3.07 fell to 1.83 (95% CI 0.63-5.30) after adjustment; nonrandom treatment, maturity imbalance, and discharge-only ascertainment prevent a causal risk estimate.
THE HOT TAKE
The raw hemangioma rate was higher with darbepoetin. This cohort cannot tell us whether the drug or the infants' greater immaturity drove it.
In a single-center retrospective cohort of 390 preterm infants, hemangioma was documented before discharge in 17/92 infants exposed to darbepoetin (18.4%), 3/36 exposed to erythropoietin (8.3%), and 18/262 with no erythropoiesis-stimulating agent (6.8%). These are unadjusted patient-level occurrences, not causal drug risks.
| Analysis |
|---|
Was this worth carrying into your next shift?
Your reaction stays connected to your NICU360 profile.
Comments
0Join the conversation
Sign in to reply, vote, and keep your participation with your NICU360 profile.